Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
NCT02194738Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2014
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
Randomised, open-label trial of erlotinib, crizotinib, nivolumab and pembrolizumab in non-small cell lung cancer (NSCLC) (11 arms), sponsored by National Cancer Institute. Primary endpoints: Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies up to 4 years and Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis up to 4 years. Started Sep 2014; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02194738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194738.